Journals Cancer Biotherapy & Radiopharm...

Cancer Biotherapy & Radiopharmaceuticals
Xiaohui Wang, Yinzi Yue, Jinhua Tan, Fei Kou, Bude Su, Jin Xie, Shuai Yan
Purpose: The study aims to explore the roles and underlying mechanisms of long noncoding RNAs endogenous bornavirus-like nucleoprotein (lncRNA EBLN3P) in colon cancer, emphasizing the potential impact of these insights on advancing colon cancer treatment strategies. By shedding light on lncRNA EBLN3P's involvement, this research could contribute to the development of novel therapeutic approaches, enhancing the efficacy of interventions for colon cancer patients. Methods: We employed quantitative reverse transcription polymerase chain reaction to assess the levels of lncRNA EBLN3P, zinc finger protein (ZFP91), and miR-519d-3p, alongside CCK-8 and EdU assays for cell proliferation, flow cytometry for apoptosis, and Transwell and wound healing assays for migration and invasion...
April 10, 2024: Cancer Biotherapy & Radiopharmaceuticals
Xiaolu Hong, Xiaoping Pan
Background: Cancer-derived exosomes facilitate chemoresistance by transferring RNAs, yet their role in exosomal microRNA-221-3p (miR-221-3p) regulation of Adriamycin resistance in breast cancer (BC) remains unclear. Methods: Adriamycin-resistant BC cells were developed from MCF-7 and MDA-MB-231 cells by incremental Adriamycin exposure. The miR-221-3p levels were quantified by quantitative reverse transcription-polymerase chain reaction. Subsequently, exosomes were isolated and incubated with BC cells, and exosome-mediated Adriamycin sensitivity was evaluated using Cell Counting Kit-8, colony formation, and flow cytometry assays...
March 26, 2024: Cancer Biotherapy & Radiopharmaceuticals
Yibo Chen, Tianyi Zhang, Rui Zhang, Xuchen Cao
Objective: Pyrotinib, a new irreversible dual pan-human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase inhibitor blocking EGFR and HER2, has achieved a promising efficacy for advanced HER2-positive (HER2+ ) breast cancer. This study intended to further investigate the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2+ breast cancer treatment. Methods: Thirty-eight HER2+ breast cancer patients who received neoadjuvant pyrotinib and trastuzumab plus chemotherapy (docetaxel and carboplatin) were retrospectively reviewed...
March 25, 2024: Cancer Biotherapy & Radiopharmaceuticals
Xun Tang, Jun Wu, Yan Chen, Daojuan Wang, Tingyu Wang, Yajing Weng, Zhengquan Zhu, Rui Peng, Yong Wang, Feng Yan
Background: Breast cancer (BC) is the most prevalent cancer among women worldwide. Although advances have been made in the identification of predictive biomarkers, current options for early diagnosis and prognostic analysis are still suboptimal. Recently, transfer-RNA-derived RNA fragments (tRFs) have emerged as a class of small noncoding RNAs that play a role in the cancer progression. The authors aimed to identify a specific class of tRFs as a molecular marker for BC diagnosis and prognosis in clinical management...
March 25, 2024: Cancer Biotherapy & Radiopharmaceuticals
Ruoyang Li, Xuewei Zhao, Yunfei Huang, Chunxiao Li, Lei Liu, Meiqi Wang, Jiaxing Wang, Zhenchuan Song
Purpose: This study aims to evaluate the short-term outcomes and prognosis and the cardiac safety of pegylated liposomal doxorubicin (PLD)-based neoadjuvant chemotherapy (NAC) compared with epirubicin-based therapy in breast cancer treatment. Methods: In total, 304 patients diagnosed with stages II and III breast cancer were enrolled that included 97 cases treated with PLD and 207 controls treated with epirubicin in NAC. The effectiveness of the antibreast cancer treatment was evaluated using overall survival (OS) and disease-free survival (DFS) metrics, whereas cardiac toxicity was measured through the left ventricular ejection fraction (LVEF) and electrocardiogram (ECG) assessments...
March 21, 2024: Cancer Biotherapy & Radiopharmaceuticals
Liwen Feng, Yuting Chen, Xiangping Mei, Lei Wang, Wenjing Zhao, Jiannan Yao
Background: Osteosarcoma (OS) is undeniably a formidable bone malignancy characterized by a scarcity of effective treatment options. Reprogramming of amino acid (AA) metabolism has been associated with OS development. The present study was designed to identify metabolism-associated genes (MAGs) that are differentially expressed in OS and to construct a MAG-based prognostic risk signature for this disease. Methods: Expression profiles and clinicopathological data were downloaded from Gene Expression Omnibus (GEO) and UCSC Xena databases...
March 21, 2024: Cancer Biotherapy & Radiopharmaceuticals
Leilei Liu, Jingyun Zhao, Hui Guo, Jingde Jia, Li Shi, Jing Ma, Zhengmao Zhang
Background: Long noncoding RNAs (lncRNAs), as emerging regulators of a wide variety of biological processes via diverse mechanisms, have been demonstrated to be of increasing importance in biology. Genome-wide association studies of tumor samples have identified several lncRNAs as either oncogenes or tumor suppressors in various types of cancers. In recent years, the importance of lncRNAs, especially in endometrioid cancer (EEC), has become increasingly well understood. The lncRNA Forkhead box P4 antisense RNA 1 (FOXP4-AS1) has been reported to fulfill roles in several types of cancers; however, the main biological function and associated underlying molecular mechanism of FOXP4-AS1 in EEC have yet to be fully elucidated...
March 20, 2024: Cancer Biotherapy & Radiopharmaceuticals
Caner Civan, Zeynep Gozde Ozkan, Berker Ozkan, Emine Goknur Isik, Eren Erdogdu, Duygu Has Simsek, Salih Duman, Yasemin Sanli, Murat Kara, Serkan Kuyumcu, Alper Toker
Purpose: The aim of this study was to evaluate the potential role of [18 F]FDG positron emission tomography/computed tomography (PET/CT) in the characterization of thymic epithelial tumors (TETs). Materials and Methods: A total of 73 patients who underwent preoperative [18 F]FDG PET/CT were included in this study. Visual total score (VTS), maximum standard uptake values (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and heterogeneity index (HI) parameters were analyzed to investigate the prediction of histopathologic grade and advanced stage...
March 14, 2024: Cancer Biotherapy & Radiopharmaceuticals
Chuang-Hsin Chiu, David J Yang, Yi-Chen Liou, Wei-Chung Chang, Tsung-Hsun Yu, Min-Ching Chung, Yen-Chun Lee, Ing-Jou Chen, Pao-Yeh Wang, Ching-Po Lin, Hey-Jen Tsay, Skye Hsin-Hsien Yeh
Background: DNA biomarkers are useful for the assessment of tumor cell proliferation. The authors aimed to synthesize a thiopurine-based ligand for evaluation of nuclear uptake and tumor localization. Materials and Methods: A 2-hydroxypropyl spacer was incorporated between a chelator (cyclam) and thiopurine ligand to produce SC-06-L1. In vitro cellular uptake and the cell/media ratios of [99m Tc]Tc-SC-06-L1 were assessed in breast (MCF-7, MDA-MB-231) and ovarian (TOV-112D, OVCAR3) cancer cells. The nuclear and cytosolic uptake ratio of [99m Tc]Tc-SC-06-L1 was determined in OVCAR-3 and MCF-7 cells...
March 8, 2024: Cancer Biotherapy & Radiopharmaceuticals
Sudipta Chakraborty, Sucheta Chatterjee, Rubel Chakravarty, Haldhar D Sarma, Raviteja Nanabala, Dibakar Goswami, Ajith Joy, Maroor Raghavan Ambikalamajan Pillai
Background : Early detection of skeletal metastasis is of great interest to determine the prognosis of cancer. Positron emission tomography-computed tomography (PET-CT) imaging provides a better temporal and spectral resolution than single photon emission computed tomography-computed tomography (SPECT-CT) imaging, and hence is more suitable to detect small metastatic lesions. Although [18 F]NaF has been approved by U.S. FDA for a similar purpose, requirement of a medical cyclotron for its regular formulation restricts its extensive utilization...
February 9, 2024: Cancer Biotherapy & Radiopharmaceuticals
Maulin P Shah
No abstract text is available yet for this article.
February 8, 2024: Cancer Biotherapy & Radiopharmaceuticals
J Harvey Turner
Patients with relapsed or refractory metastatic cancer unresponsive to standard therapies have motivated nuclear physicians to develop innovative radioligands, precisely targeted to tumor molecular receptors, for effective treatment of specific advanced malignancies. Individual practitioners in departments of nuclear medicine across the world have performed first-in-human studies on compassionate patient usage N-of-One protocols. These physician-sponsored studies then evolved into early-phase clinical trials and obtained real-world data to demonstrate real-world evidence of effectiveness in prolonging survival and enhancing quality of life of many so-called "End-Stage" cancer patients...
February 7, 2024: Cancer Biotherapy & Radiopharmaceuticals
Jing Ai, Shuang Zhang, Yimeng Qian, Lin Kang, Litao Zhang, Jing Zhao
Background: Malignant glomus tumors (MGTs) are rare malignancies, which grow rapidly and are aggressive. Surgical resection has been regarded as the standard management, but treatment options for those unresectable tumors are limited, resulting in a high recurrence rate and poor prognosis. Case Description: An 85-year-old man presented with gross hematuria and was diagnosed with MGTs of bladder. The patient achieved long-term local control after multimodal therapy comprising radiotherapy, iodine-125 seeds brachytherapy, transcatheter arterial chemoembolization, and antiangiogenic targeted therapy...
February 7, 2024: Cancer Biotherapy & Radiopharmaceuticals
Pardeep Kumar, Aishwarya Kumar, Chandana Nagaraj, Nishanth Sadashiva, Jitender Saini, Sandhya Mangalore, Archith Rajan, Keerti Sitani, Manish Beniwal, Vani Santosh, Harish Basavaraja, Puja Panwar Hazari, Anil Kumar Mishra
Background: Amino acid positron emission tomography (PET) imaging plays a significant role in the diagnosis of gliomas and in differentiating tumor recurrence from necrosis. In this study, the authors have evaluated the diagnostic efficacy of [99m Tc]Tc-methionine single-photon emission computed tomography-computed tomography (SPECT-CT) in comparison with [11 C]methionine PET-magnetic resonance imaging (MRI) in delineating tumors. Methods: Thirty-one (primary: 16 and postoperative: 15) patients of confirmed (either MRI or histopathological proven) glioma underwent both [99m Tc]Tc-methionine SPECT-CT and [11 C]methionine PET-MRI...
February 7, 2024: Cancer Biotherapy & Radiopharmaceuticals
Bilal Kovan, Dilara Denizmen, Caner Civan, Serkan Kuyumcu, Emine Goknur Isik, Duygu Has Simsek, Zeynep Gozde Ozkan, Arzu Poyanli, Bayram Demir, Yasemin Sanli
Purpose: The aim of this study was to evaluate the effect of an increase in the time interval between hepatic intra-arterial injection of 99mTc-macroaggregated albumin (MAA) and hepatic artery perfusion scintigraphy (HAPS) on the lung shunt fraction (LSF) and perfused volume (PV) calculations in the treatment planning of selective internal radiation therapy (SIRT). Methods: The authors enrolled 51 HAPS sessions from 40 patients diagnosed with primary or metastatic liver malignancy. All patients underwent scan at the first and fourth hour after hepatic arterial injection of 99mTc-MAA...
January 24, 2024: Cancer Biotherapy & Radiopharmaceuticals
Tom B├Ąck, Per Albertsson, Emma Aneheim, Ragnar Hultborn, Lars Jacobsson, Sture Lindegren, Stig Palm
Background: Real-time quantification of radioligand binding to cells under in vivo -like conditions improves evaluation of clinical potential. Materials and Methods: SKOV-3 tumor cells were grown in a monolayer on a thin glass plate placed in a sealable shallow chamber with a continuous flow of 125 I-trastuzumab solution. The time-dependent cell binding was measured using a NaI detector, and the binding parameters were derived by computational analysis. Results: The detection efficiency of 125 I was 65 cps/kBq for radioligand bound to the cells...
January 23, 2024: Cancer Biotherapy & Radiopharmaceuticals
K V Vimalnath, Ardhi Rajeswari, Anupam Dixit, Rubel Chakravarty, Haldhar D Sarma, Suyash Kulkarni, Ashish Jha, Ameya Puranik, Venkatesh Rangarajan, Madhumita Goswami, Sudipta Chakraborty
Background: Selective internal radiation therapy (SIRT) using a suitable β-emitting radionuclide is a promising treatment modality for unresectable liver carcinoma. Yttrium-90 [ T 1/2  = 64.2 h, E β (max) = 2.28 MeV, no detectable γ-photon] is the most preferred radioisotope for SIRT owing to its favorable decay characteristics. Objective: The present study describes indigenous development and evaluation of intrinsically radiolabeled [90 Y]yttria alumino silicate ([90 Y]YAS) glass microsphere, a formulation biosimilar to "TheraSphere" (commercially available, U...
January 23, 2024: Cancer Biotherapy & Radiopharmaceuticals
Aarti Aggarwal, Gurjeet Kaur, Ravjit Singh Jassal, Bikash Medhi, Bhagwant Rai Mittal, Jaya Shukla
Introduction: Hepatocellular carcinoma is a prevalent contributor to global mortality rates. The main palliative treatments are trans-arterial chemoembolization and selective intra-arterial radionuclide therapy. Methods: A novel freeze-dried nonradioactive microsphere kit formulation has been developed, and the behavior and therapeutic potential of 188 Re microspheres have been assessed. The microspheres were labeled with fluorescein isothiocyanate (FITC) and 188 ReO4 - . The uptake of FITC microspheres by HepG2 cells was examined at various time intervals...
January 19, 2024: Cancer Biotherapy & Radiopharmaceuticals
Ali Aljubran, Ahmed Badran, Mohamed Alrowaily, Hussein Raef, Ahmed M Alzahrani, Ahmed Almuhaideb, Hadeel Almanea, Abdelmoneim El-Dali, Mahmoud Tuli, Shouki Bazarbashi
Background: Both everolimus and peptide receptor radionuclide therapy (PRRT) are approved as monotherapies for advanced neuroendocrine tumors (NETs). Research in animal models showed synergism between the two treatment modalities. This study evaluate the safety and efficacy of combining everolimus and PRRT for the treatment of unresectable NETs. Methods: Adult patients (≥18 years) with progressing and unresectable histologically confirmed grade 1-2 NETs of all origins were enrolled. Everolimus was started at a 5 mg daily dose and was increased after the initial three patients to 10 mg daily...
March 2024: Cancer Biotherapy & Radiopharmaceuticals
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.